Novel peptide linker-based nectin-4 targeting ADC shows improved tolerability with long-lasting anti-tumor efficacy at low doses

被引：2
|
作者：
Attinger-Toller, Isabella
Probst, Philipp
Bertrand, Romain
Renard, Emma
Stark, Ramona
Santimaria, Roger
Grabulovski, Dragan
Schlereth, Bernd
Spycher, Philipp Rene
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-LB221
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB221
引用
收藏
页数：2
相关论文
共 9 条
  • [1] Inducing complete and long-lasting tumor eradications at safe and well tolerated doses of a nectin-4 ADC generated with novel peptide linkers for payload conjugation.
    Attinger-Toller, Isabella
    Probst, Philipp
    Bertrand, Romain
    Stark, Ramona
    Santimaria, Roger
    Grabulovski, Dragan
    Schlereth, Bernd
    Spycher, Philipp
    CANCER RESEARCH, 2022, 82 (12)
  • [2] Enfortumab vedotin, a Nectin-4 directed ADC, demonstrates compelling tolerability and anti-tumor activity with intravesical instillation in preclinical models of non-muscle invasive bladder cancer
    Carosino, Christopher
    Olson, Devra
    Snead, Katie
    Lee, Anthony
    Farr, Lauren
    Garg, Amit
    O'Day, Christine
    Trueblood, Esther
    Wright, Jennifer
    Bieda, Mark
    Caldwell, Charles
    Hensley, Kelly
    Allred, Sean
    Liu, Bernard
    Shimazaki, Masashi
    Sandall, Sharsti
    CANCER RESEARCH, 2022, 82 (12)
  • [3] TUB-040, a novel Napi2b-targeting ADC built with ethynylphosphonamidate conjugation chemistry, demonstrates high and long-lasting anti-tumor efficacy via Topoisomerase-I inhibition and excellent tolerability predictive of a wide therapeutic window in humans
    Schmitt, Saskia
    Mai, Isabelle
    Machui, Paul
    Herterich, Sarah
    Hauswald, Danila
    Ochtrop, Philipp
    Cyprys, Philipp
    Kozlowska, Izabela
    Kitowski, Annabel
    Gerlach, Marcus
    Marcq, Olivier
    Trail, Pamela A.
    Schumacher, Dominik
    Kasper, Marc-Andre
    Fingerle-Rowson, Guenter
    Hock, Bjorn
    Helma-Smets, Jonas
    Vogl, Annette M.
    CANCER RESEARCH, 2024, 84 (06)
  • [4] Using a novel NextGen linker system to generate a conditionally active biologic (CAB) anti-nectin4-ADC demonstrates improved efficacy in pancreatic PDX cancer models and improved tolerability and toxicity profile in non-human primates
    Wang, Jing
    Chen, Jian
    Frey, Gerhard
    Liu, Haizhen
    Xing, Charles
    Woodard, Kathryn
    Chang, Hwai
    Boyle, William J.
    Short, Jay M.
    CANCER RESEARCH, 2024, 84 (06)
  • [5] Enabling 5T4 for targeted cancer therapy: TUB-030, a novel ADC built with ethynylphosphonamidate conjugation chemistry, shows long-lasting anti-tumor activity via Topoisomerase-I inhibition with an optimized therapeutic index
    Schmitt, Saskia
    Mai, Isabelle
    Machui, Paul
    Herterich, Sarah
    Hauswald, Danila
    Ochtrop, Philipp
    Cyprys, Philipp
    Kozlowska, Izabela
    Kitowski, Annabel
    Gerlach, Marcus
    Marcq, Olivier
    Trail, Pamela A.
    Schumacher, Dominik
    Kasper, Marc-Andre
    Fingerle-Rowson, Guenter
    Hock, Bjorn
    Helma-Smets, Jonas
    Vogl, Annette M.
    CANCER RESEARCH, 2024, 84 (06)
  • [6] A 211At-labelled mGluR1 inhibitor induces cancer senescence to elicit long-lasting anti-tumor efficacy (Vol 4, 100960, 2023)
    Xie, Lin
    Zhang, Lulu
    Hu, Kuan
    Hanyu, Masayuki
    Zhang, Yiding
    Fujinaga, Masayuki
    Minegishi, Katsuyuki
    Ohkubo, Takayuki
    Nagatsu, Kotaro
    Jiang, Cuiping
    Shimokawa, Takashi
    Ashisuke, Kazuma
    Okonogi, Noriyuki
    Yamada, Shigeru
    Wang, Feng
    Wang, Rui
    Zhang, Ming-Rong
    CELL REPORTS MEDICINE, 2025, 6 (02)
  • [7] An exatecan derivative based linker-payload platform leads to ADC products with promising anti-tumor efficacy and potential low interstitial lung disease (ILD) risk
    Lin, S.
    Shi, R.
    Li, B.
    Qiu, Y.
    Hua, H.
    Zhang, Y.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S91 - S91
  • [8] A novel synthetic long peptide vaccine composition targeting multiple PD-L1 T-cell epitopes exhibits anti-tumor efficacy in a syngeneic mouse colorectal cancer model
    Lin, Kenneth Nansheng
    Toh, Melvin
    CANCER RESEARCH, 2024, 84 (06)
  • [9] The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models
    Hicks, Stuart W.
    Tarantelli, Chiara
    Wilhem, Alan
    Gaudio, Eugenio
    Li, Min
    Arribas, Alberto J.
    Spriano, Filippo
    Bordone, Roberta
    Cascione, Luciano
    Lai, Katharine C.
    Qiu, Qifeng
    Taborelli, Monica
    Rossi, Davide
    Stussi, Georg
    Zucca, Emanuele
    Stathis, Anastasios
    Sloss, Callum M.
    Bertoni, Francesco
    HAEMATOLOGICA, 2019, 104 (08) : 1633 - 1639
1